Wednesday, July 8, 2026
🇺🇸 FDA

biotech · Colorectal Cancer · Psoriatic Arthritis, Rheumatoid Arthritis · CRDF

Cardiff Oncology

Cardiff Oncology clinical programs — 31 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
11055 Flintkote Avenue, San Diego, California 92121, US HQ
1999 Founded
51 Employees
Public company Type
CRDF · NYSE Ticker
Company details
Status
Public
HQ
11055 Flintkote Avenue, San Diego, California 92121, US
Founded
1999
Employees
51
Programs
58
Drugs
62
Patents
69
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Cardiff Oncology projects

31 ClinicalTrials.gov programs sponsored by Cardiff Oncology.

Cardiff Oncology has 31 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

31 programs

Clinical programs

  1. AZD5363

    Cardiff Oncology

    Estrogen Receptor Positive Breast Cancer

    phase 2 small molecule active

    1 trial

  2. Aspirin

    Cardiff Oncology

    Venous Leg Ulcer

    phase 2 small molecule terminated

    1 trial

  3. Colonoscopy with enhanced dye

    Cardiff Oncology

    Colorectal Cancer

    phase 2 other completed

    1 trial

  4. FOLFIRI regimen

    Cardiff Oncology

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Cardiff Oncology

    Anal cancer

    phase 2 small molecule active

    1 trial

  6. LAB4

    Cardiff Oncology

    Graves' Disease

    phase 2 mab active

    1 trial

  7. Leucovorin

    Cardiff Oncology

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  8. Low Molecular Weight Heparin (LMWH)

    Cardiff Oncology

    Cancer

    phase 2 small molecule terminated

    1 trial

  9. Motivational Interviewing

    Cardiff Oncology

    Diabetes Mellitus

    phase 2 other terminated

    1 trial

  10. Onvansertib

    Cardiff Oncology

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule completed

    1 trial

  11. Onvansertib

    Cardiff Oncology

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  12. Onvansertib

    Cardiff Oncology

    Breast Cancer

    phase 2 small molecule active

    1 trial

  13. Onvansertib

    Cardiff Oncology

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  14. Onvansertib

    Cardiff Oncology

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    2 trials

  15. Onvansertib

    Cardiff Oncology

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  16. Onvansertib

    Cardiff Oncology

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  17. Onvansertib

    Cardiff Oncology

    Small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. Paclitaxel

    Cardiff Oncology

    Carcinosarcoma

    phase 2 small molecule active

    1 trial

  19. Placebo

    Cardiff Oncology

    Metastatic Breast Cancer

    phase 2 small molecule terminated

    1 trial

  20. Placebo

    Cardiff Oncology

    Tuberous Sclerosis

    phase 2 small molecule active

    1 trial

  21. Plerixafor

    Cardiff Oncology

    Acute Myeloid Leukaemia

    phase 2 small molecule completed

    1 trial

  22. Ponatinib

    Cardiff Oncology

    Acute Lymphoblastic Leukemia, Adult

    phase 2 small molecule active

    1 trial

  23. Pro insulin peptide

    Cardiff Oncology

    Type 1 Diabetes

    phase 2 small molecule completed

    1 trial

  24. SPON - 1751-19

    Cardiff Oncology

    Blood cancer

    phase 2 small molecule active

    1 trial

  25. Tyenne 162 mg solution for injection in pre-filled pen

    Cardiff Oncology

    Psoriatic Arthritis, Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  26. Tyenne 162 mg solution for injection in pre-filled pen

    Cardiff Oncology

    Psoriatic Arthritis, Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  27. Vancomycin

    Cardiff Oncology

    Late Onset Neonatal Sepsis

    phase 2 small molecule terminated

    1 trial

  28. capecitabine

    Cardiff Oncology

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  29. carboplatin

    Cardiff Oncology

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  30. cisplatin

    Cardiff Oncology

    Bladder Cancer

    phase 2 small molecule completed

    2 trials

  31. sirolimus

    Cardiff Oncology

    Tuberous Sclerosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Cardiff Oncology have?

31 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.